Allogeneic hematopoietic cell transplantation (HCT) has been increasingly used in the setting of FMS-like tyrosine kinase-3 (FLT3)-mutated AML. However, its role in conferring durable relapse-free intervals remains in question. Herein we sought to investigate FLT3 mutational status on transplant outcomes. We conducted a retrospective cohort study of 262 consecutive AML patients who underwent first-time allogeneic HCT (2008HCT ( -2014, of whom 171 had undergone FLT3-ITD (internal tandem duplication) mutational testing. FLT3-mutated AML was associated with nearly twice the relapse risk (RR) compared with those without FLT3 mutation 3 years post-HCT (63% vs 37%, P o0.001) and with a shorter median time to relapse (100 vs 121 days). FLT3 mutational status remained significantly associated with this outcome after controlling for patient, disease and transplant-related risk factors (Po 0.05). Multivariate analysis showed a significant association of FLT3 mutation with increased 3-year RR (hazard ratio (HR) 3.63, 95% confidence interval (CI): 2.13, 6.19, Po 0.001) and inferior disease-free survival (HR 2.05, 95% CI: 1.29, 3.27, P o 0.01) and overall survival (HR 1.92, 95% CI: 1.14, 3.24, Po 0.05). These data demonstrate high risk of early relapse after allogeneic HCT for FLT3-mutated AML that translates into adverse disease-free and overall survival outcomes. Additional targeted and coordinated interventions are needed to maintain durable remission after allogeneic HCT in this high-risk population.
INTRODUCTION
AML is a genetically heterogeneous disease. 1 Acquired somatic mutations in the FMS-like tyrosine kinase-3 (FLT3) gene occur in up to 20-30% of AML patients who carry the internal tandem duplication (ITD) mutation.
2-4 FLT3-ITD has been characterized as a gain-of-function mutation with constitutive activation of receptor tyrosine kinase FLT3. 5 This alteration has been associated with adverse prognosis in both pediatric and adult AML patients. 4, 6 Allogeneic hematopoietic cell transplantation (HCT) is an important treatment option for patients with AML. 7 Unfortunately, disease recurrence and transplant-related toxicity remain the major causes of treatment failure. 8 Accordingly, the value of allogeneic HCT in conferring durable long-term remission-free intervals continues to be an important consideration, particularly in patients with FLT3 gene mutation.
FLT3 mutation as an independent risk factor for allogeneic transplant outcomes has previously been explored by several groups through single institution and multicenter registry studies, with inconsistent reports depending on the study population. Unfortunately, many of these studies have been restricted to cytogenetically normal AML, small sample sizes or specific conditioning or donor types, thereby limiting the generalizability of the findings. Although allogeneic HCT with the best available donor has become widely adopted as an important therapeutic option in AML patients with FLT3 mutation who achieve first CR (CR1), there may be additional patient, disease or transplantspecific variables that increase relapse hazards. 8 Therefore, in the present study we investigated the impact of FLT3 mutational AML on relapse risk (RR), non-relapse mortality (NRM), disease-free survival (DFS) and overall survival outcomes following allogeneic HCT at a single institution between 2008 and 2014. The study design included a retrospective cohort analysis and detailed characterization of patient, disease and transplant-specific factors by FLT3 mutational status (positive vs negative).
PATIENTS AND METHODS

Literature review
As the focus of this paper was FLT3 mutational AML in allogeneic HCT, we conducted a literature search in PubMed/MEDLINE. The search was performed in January 2015 and was restricted to studies published in English within the past 20 years . Three MeSH terms, 'transplantation' 'FLT3' and 'acute myelogenous leukemia' were used in the search, in addition to various combinations of 'HCT' 'FMS-like tyrosine kinase 3', 'acute myeloid leukemia' and 'AML.' The initial search resulted in a total of 300 articles. Two co-authors (YS and SWC) screened a random half set of the abstracts; 277 were determined as not meeting the inclusion criteria. Both authors read the full text of the remaining 23 papers. Each of 1 these papers was reviewed in depth, with key outcomes summarized in Supplementary Table S1 .
Study design
A retrospective cohort study was conducted on 262 pediatric and adult AML patients undergoing first-time allogeneic HCT between January 2008 and July 2014. The study was approved by the University of Michigan Institutional Review Board (IRBMED no. HUM00095617). Informed consents were obtained from all subjects, and data were collected under the IRBMED-approved protocol (IRBMED no. HUM43287). Routine FLT3 mutational testing for AML began in 2008 at the University of Michigan. Twenty-three patients who either had FLT3-TKD mutation without FLT3-ITD or who received umbilical cord blood transplantation were excluded from the study to reduce potential confounding. An additional 65 patients who did not undergo FLT3 mutational testing were excluded from the analysis. Details of the patient, disease and transplant-related characteristics and outcomes are provided in Supplementary Tables S2-S4 . The total study population was 171 patients with known FLT3 mutational status (positive vs negative). Cytogenetic and molecular testing (FLT3 and NPM1) was performed at the University of Michigan or at referring institutions.
Data abstraction of patient, disease and transplant-related variables was performed through manual chart review of the Electronic Medical Record system (Careweb and MiChart/EPIC), supported by the University of Michigan Electronic Medical Record Search Engine (EMERSE). EMERSE is designed to comprehensively search all institutional clinical documents using specified search terms and queries. 32 Documents screened by EMERSE were examined in further detail for relevant study data. Outcomes of the study included RR, GVHD, NRM, DFS and overall survival.
Patient, disease and transplant-related characteristics Patient characteristics included age, gender, race, ethnicity and body mass index (BMI) at the time of allogeneic HCT. A hematopoietic cell transplantation-specific comorbidity index (HCT-CI) score was calculated using documented clinical and laboratory data for each patient in the study, as previously described. 33 Disease features included WBC count at diagnosis, Center for International Blood and Marrow Transplant Research (CIBMTR) cytogenetic risk based on karyotype at diagnosis (noting the presence or absence of complex cytogenetics (⩾3 abnormalities)), 34 NPM1 mutational status, antecedent myelodysplastic syndrome or myeloproliferative disorder and therapy-related AML. Morphological status at transplant, defined as persistent disease (⩾5% blasts) vs CR (o 5% blasts), and cytogenetic remission status at transplant, defined as normal karyotype without clonal abnormalities, were also collected. Time from diagnosis to transplantation (infusion of allogeneic hematopoietic cells) was recorded (⩾180 vs o180 days).
Transplant-related characteristics included the number of pretransplant chemotherapy cycles (induction and consolidation), conditioning intensity (myeloablative or reduced), use of thymoglobulin or alemtuzumab, TBI (⩾1200 cGy), stem cell source (bone marrow or peripheral blood), donor-recipient characteristics (gender, related or unrelated, HLA matched (8/8) or mismatched (7/8), ABO and Rh blood type and CMV status), number of CD34+ cells transfused and length of hospital stay. Additional characteristics included GVHD prophylaxis (calcineurin inhibitormethotrexate or calcineurin inhibitor-mycophenolate mofetil) and time to neutrophil engraftment (defined as the first of 3 consecutive days with ANC ⩾ 500/mm 3 ).
Statistical analysis
Statistical analyses were performed using R 3.02 (GNU General Public License), with α = 0.05 defining the level of statistical significance (two-sided). Summary data were calculated for patient, disease and transplant-related variables, with medians and ranges determined for continuous variables and counts and percentages calculated for categorical variables. The cohort was then sub-divided into two groups based on their FLT3 mutational status, and statistically significant differences between these groups were assessed using the Kruskal-Wallis test for continuous variables and the χ 2 test of association for categorical variables. The Fine-Gray method 35 was used to determine cumulative incidences with competing risks, which were then compared using the K-sample tests described by Gray. 36 The Kaplan-Meier method was used to compute overall survival. 37 Univariate regression methods (competing risks regression for RR, acute and chronic GVHD and NRM and Cox regression for DFS and overall survival) were used to model the marginal associations of FLT3 mutational status and other patient, disease and transplant-related variables with clinical outcomes. Bivariate models were used to further determine the joint association of FLT3 mutation and key variables with outcomes. Because complex cytogenetic changes are used in CIBMTR cytogenetic risk determination, this variable was excluded from bivariate and multivariate modeling. Morphological status (persistent disease vs CR) was also included in modeling, because refractory disease status at the time of allogeneic HCT has previously been shown to be an independent poor prognostic factor. 27 Multivariate regression models using backward selection were used to identify best-fitting models for outcomes containing FLT3 mutational status and other possible confounders identified in descriptive characteristic comparison and univariate and bivariate testing.
RESULTS
Characteristics by FLT3 mutational status A total of 171 consecutive AML patients with available FLT3 mutational testing received first-time allogeneic HCT. The median age of the study population was 55 years (range: 1 − 72 years). Age, gender, race, BMI and HCT-CI distributions were similar in patient groups with vs without FLT3 mutation. The remaining patient and disease characteristics are detailed in Table 1 .
The groups were also similar in morphological status at the time of HCT (persistent disease vs CR), time from diagnosis to HCT (4180 vs ⩽ 180 days) and number of induction (42 vs ⩽ 2) and combined induction and consolidation chemotherapy cycles leading to HCT (median of three cycles for both groups). Significantly more FLT3-positive than FLT3-negative patients were in cytogenetic remission at the time of HCT (94% vs 71%, Po 0.01). As expected, the FLT3-mutated group had higher WBC counts (⩾10 000/μL) at the time of diagnosis (70% vs 36%, Po 0.001), predominantly intermediate-risk CIBMTR cytogenetics with fewer instances of complex cytogenetics at diagnosis (0% vs 21%, P o0.001) and higher co-occurrence with NPM1 mutation (38% vs 11%, P o 0.001). FLT3 mutation was less often observed in cases of preceding myelodysplastic syndrome or myeloproliferative disease (8% vs 26%, P o 0.01) and therapy-related AML (0% vs 9%, P o0.05).
Transplant-related characteristics were also similar between the groups, including stem cell source, donor-recipient characteristics, conditioning intensity, use of thymoglobulin or alemtuzumab, TBI, number of CD34+ cells transfused, length of hospital stay, GVHD prophylaxis and time to neutrophil engraftment ( Table 2 ).
Engraftment and neutrophil recovery G-CSF was started 6 days after transplantation to promote neutrophil engraftment. The majority of surviving patients (499%) engrafted within 50 days of allogeneic HCT (Table 2) . There was one case of graft failure among patients without FLT3 mutation. Figure 1 illustrates the 3-year cumulative incidence outcomes of the patient cohort following allogeneic HCT, stratified by FLT3 mutational status. Patients with FLT3 mutation experienced shorter median time to relapse (100 days, range: 25 − 495 days) compared with those without FLT3 mutation (121 days, range: 26 − 1142 days). The risk of relapse at 3 years was significantly higher in FLT3-mutated patients (63% vs 37%, P o 0.001). Among the other variables tested, high HCT-CI, high CIBMTR cytogenetic risk and complex cytogenetics were also significantly associated with increased RR at 3 years (Table 3) . We also performed bivariate analyses to explore the individual interactions of FLT3 mutation with age, HCT-CI, CIBMTR cytogenetic risk, NPM1 status, number of induction chemotherapy cycles, morphological status and conditioning intensity and found that FLT3 mutation remained a 
Risk of relapse
39 (23) 26 (21) 13 (26) (40) 49 (40) 19 (38) HCT-CI Low risk 34 (20) 22 (18) 12 (24) (Table 5) . Abbreviations: CSA = cyclosporine; FLT3 = FMS-like tyrosine kinase-3; MMF = mycophenolate mofetil; MTX = methotrexate; Tac = tacrolimus. FLT3 mutational status (positive vs negative).
FLT3
GVHD (acute and chronic)
The median time to onset of grade 2 − 4 acute GVHD in the study population was 36 days (range: 10 − 180 days) and the cumulative incidence at 1 year after HCT was 33%, which was similar in patients with vs without FLT3 mutation (30% vs 34%, respectively, P = 0.715). None of the other variables tested in the univariate analysis was significantly associated with 1-year acute GVHD outcomes (Table 3) . We also assessed the impact of FLT3 mutational status on chronic GVHD. The median onset of chronic GVHD in the study population was 161 days (range: 52 − 580 days) with a cumulative incidence of 49% at 1 year following HCT, which was significantly lower among patients with vs without FLT3 mutation (36% vs 54%, P o0.05). WBC count ⩾ 10 000/μL at diagnosis was also associated with decreased risk of chronic GVHD (41% vs 54%, P o 0.05). In the bivariate analysis, FLT3 mutation was associated with significantly lower incidence of chronic GVHD, even after adjusting for age, HCT-CI score, CIBMTR cytogenetic risk, number of induction cycles, morphological status and conditioning intensity (Table 4) . Additionally, after incorporating all of these characteristics in the multivariate model, FLT3 mutation remained the only variable significantly associated with decreased risk of chronic GVHD (HR 0.44, 95% CI: 0.25, 0.78, P o 0.01, Table 5 ).
Non-relapse mortality NRM at 3 years was significantly lower in patients with FLT3 mutation (4% vs 21%, respectively, P o 0.05, Figure 1 ). Although time from AML diagnosis to HCT (4180 vs ⩽ 180 days) did not impact the risk of NRM, patients who received 42 induction chemotherapy cycles experienced higher NRM (32% vs 12%, respectively, P o0.05; Table 3 ). On bivariate testing, FLT3 mutation remained significantly associated with decreased NRM after adjusting for age, HCT-CI, CIBMTR cytogenetic risk, NPM1 status, number of induction cycles, morphological status and conditioning intensity (Table 4 ). This finding was also seen in the multivariate analysis (HR 0.21, 95% CI: 0.05, 0.92, P o 0.05).
Disease-free survival FLT3 mutational status was associated with a trend toward inferior DFS at 3 years (FLT3 mutation: 32% vs no FLT3 mutation: 41%, P = 0.065, Figure 1 ). CIBMTR cytogenetic risk (high: 13% vs intermediate: 45% vs low: 100%, P = 0.001), complex cytogenetics (⩾3 abnormalities at diagnosis: 11% vs o3 abnormalities: 44%, P o0.001), and number of induction cycles (42 inductions: 15% vs ⩽ 2 inductions: 46%, P o0.01) variables at diagnosis were associated with significantly decreased DFS (Table 3 ). In the bivariate models, FLT3 mutation was shown to negatively impact DFS when adjusting for CIBMTR cytogenetic risk and NPM1 status variables only (Table 4) . However, in the multivariate model that accounted for the interaction of multiple potential confounders, FLT3 mutation (HR 2.05, 95% CI: 1.29, 3.27, P o0.01), high CIBMTR cytogenetic risk (HR 2.35, 95% CI: 1.34, 4.10, Po 0.01), 42 induction cycles (HR 1.73, 95% CI: 1.07, 2.78, P o0.05) and persistent morphological disease at the time of transplant (HR 2.52, 95% CI: 1.51, 4.21, P o0.001) were all found to be significantly associated with inferior DFS (Table 5) .
Overall survival
The 3-year overall survival was decreased among patients with vs without FLT3 mutation, but the difference was not statistically significant (38% vs 48%, P = 0.334, Figure 1 ) with a median survival of 244 days (range: 57-2001 days) and 368 days (range: 46-2405 days), respectively. Among the other variables tested, high CIBMTR cytogenetic risk, presence of complex cytogenetics at diagnosis and 42 induction chemotherapy cycles were each associated with significantly lower 3-year overall survival (Table 3 ).
In the bivariate models, FLT3 mutation negatively impacted overall survival (HR 1.69, 95% CI: 1.04, 2.75, P o0.05) after adjusting for CIBMTR cytogenetic risk at diagnosis only ( (Table 5 ). All causes of mortality are detailed in Supplementary Table S5 .
DISCUSSION
In this study, we examined the frequency of FLT3 mutation in children and adults with AML who underwent allogeneic HCT at our center over a 7-year study period. Patients diagnosed before 2007 were not genetically defined for this mutation at diagnosis. Given conflicting reports, 9-31 we sought to further clarify the impact of FLT3 mutational status on HCT outcomes in a large, Abbreviations: aGVHD = acute GVHD; cGVHD = chronic GVHD; CIBMTR = Center for International Blood and Marrow Transplant Research; DFS = disease-free survival; FLT3 = FMS-like tyrosine kinase-3; HCT-CI = Hematopoietic Cell Transplantation-Specific Comorbidity Index; NRM = non-relapse mortality; RR = relapse risk. FLT3 mutational status (positive vs negative).
FLT3 AML and allogeneic hematopoietic cell transplantation Y Song et al Table 4 . Bivariate analysis results [2] [3] [4] We found that FLT3 mutation was an independent factor for increased RR that translated into inferior DFS and overall survival after adjusting for potential confounding covariates. The low NRM was likely due to a higher RR, which is a competing risk for NRM. The present findings extend the observations from previous studies that have reported the outcomes of FLT3 mutational AML after allogeneic HCT (Supplementary Table S1 ) and substantiate the need for optimizing risk stratification of AML patients at the time of transplant.
Cytogenetic characterization at diagnosis is recognized as the most powerful independent prognostic factor in AML. In recent years, risk stratification has been refined by molecular markers, such as the FLT3 gene. Herein our data support the importance of carefully characterizing disease-specific variables in AML patients presenting for allogeneic transplantation. Our analyses demonstrate that, in addition to FLT3 mutation, high-risk CIBMTR cytogenetics at diagnosis and persistent morphological disease at transplant conferred an increased RR and lowered DFS and overall survival.
Recently, the number of induction courses required to achieve morphological remission in AML was shown to provide independent prognostic information for outcome after transplant. 38 We therefore included this variable in our analyses and similarly demonstrated that patients who received 42 induction cycles experienced decreased DFS and overall survival. These data provide insight into disease-specific factors that independently contribute to relapse and highlight the need to identify allogeneic HCT candidates for risk-stratified treatment recommendations. For example, patients who are destined to relapse early after allogeneic HCT (FLT3 mutation, high CIBMTR risk cytogenetics and/or persistent morphological disease) may benefit from posttransplant interventions or other non-transplant clinical trial options. Unfortunately, there remains a paucity of prospective, multicenter studies that have rigorously evaluated such strategies, such as donor leukocyte infusions, 39 targeted therapies, 40 hypomethylating agents 41 or other immune checkpoint blockade therapy. 42 The optimal timing, dosing, duration and type of strategy in the post-transplant setting are unknown and need to be explored.
Interestingly, FLT3-mutated patients with intermediate CIBMTR cytogenetic risk experienced increased RR similar to those with high CIBMTR cytogenetic risk (data not shown). However, DFS and overall survival were not as comparably reduced as seen in the high CIBMTR cytogenetic risk group. These data again highlight the potential role for implementing preemptive FLT3-targeted therapies to reduce the relapse hazard in these molecularly defined patients.
Like recent studies examining the influence of age on allogeneic HCT outcomes, 43 our study did not indicate that patients aged 460 years experienced increased relapse or decreased survival. It is possible that our data represent selection of older individuals with greater fitness who met institutional criteria for allogeneic HCT or treatment according to a clinical trial. Nonetheless, we further explored other patient-specific comorbid conditions as measured by the HCT-CI 33 to help estimate outcomes following transplant and found that high HCT-CI was associated with increased RR. Although not statistically significant, this resulted in a trend toward inferior DFS and overall survival. Allogeneic HCT is increasingly offered to older patients, and identifying suitable patients could improve the effectiveness of transplantation. In our study, myeloablative conditioning was associated with lower RR and increased DFS and overall survival, suggesting a potentially protective effect in this population. It is possible that a subset of chronologically older age individuals would benefit from and tolerate increased intensity regimens. Nonetheless, we recognize that further work is needed to confirm our observations. We recognize the limitation of our single-center, retrospective cohort study. Nonetheless, allogeneic HCT is increasingly a preferred treatment option for FLT3 mutational AML patients, particularly with increased availability of donors and use of reduced intensity conditioning regimens, and such studies provide direction for well-designed prospective clinical trials. There is ongoing need to develop novel, preemptive posttransplant strategies in the setting of clinical research, particularly for high-risk AML, to help address malignant relapse. 44 Our study supports the recognition of FLT3 mutation as an independent marker for high-risk disease and highlights the importance of carefully examining disease, patient and transplant-specific variables, collectively, to identify suitable allogeneic HCT candidates and inform posttransplant expectations. Furthermore, minimal residual disease monitoring has been increasingly recognized as a source of additional valuable prognostic information that complements molecular and cytogenetic risk, 45 and combined utilization of these factors may prove crucial to optimal prognostication.
Strengths of our study include transplant practices in the current era (2008-2014) with detailed patient, disease and transplant-specific variables. To our knowledge, based on the literature review (detailed in Supplementary Table S1) the present analysis represents one of the largest study populations with known FLT3 mutational status who have undergone allogeneic HCT with the best available donor (related or unrelated) after either myeloablative or reduced intensity conditioning. At the same time, we recognize that the heterogeneity of this patient population is also a limitation, precluding us from forming generalized conclusions, such as in pediatric patients. We performed a sub-group analysis of children aged o 18 years, and although the sample size was small, we observed similar trends in outcomes between the overall study population and pediatric patients (data not shown). We attempted to control for potential confounding covariates by performing both bivariate and multivariate analyses. Clearly, future studies are needed with larger populations from multicenter collaborations to confirm the observations herein.
In summary, the key finding of this study is the adverse outcomes associated with FLT3-mutant AML. The data herein highlight the early kinetics of malignant relapse occurring within the first 100 days of transplanted patients. Therefore, it is desirable to develop novel post-transplant strategies that could effectively impact early relapse hazards.
